Moderna’s RSV Vaccine Sparks Alarming Safety Concerns: Hospitalized Infants and FDA Oversight

FULL CLIP: https://rumble.com/v61sy2e-mrna-vaccines-pose-ongoing-concerns-in-children-airdate-december-19-2024.html?mref=1bxo9j&mc=69gy3

The Jaxen Report: "So we have, now let's stay on the vaccine conversation because a lot of these manufacturers like Pfizer, like Moderna, they had such a great success with the COVID vaccine that they're moving on to other vaccines. Moderna is moving on to the RSV vaccine."

"This is a respiratory virus. It can have complications if you're older, immune suppressed or very, very young children. And that's where they're testing it in. They're testing it in kids in Panama. five months to seven months old. So extremely small infants here for this RSV vaccine test. And there's a problem."

"There's what they call a safety signal, a little bit of a roadblock, but don't worry, they'll get around that roadblock. That's what the headlines say. And you can look at this, Moderna's RSV vaccine run into safety roadblock. What kind of roadblock? Well, it's in the study, there's five cases of severe to very severe lower RSV respiratory tract infections."

"Those were reported among. 40 of the babies who received the dose compared to just one in the placebo group. What happened to those babies, those infants? Five of them, all of them required hospitalization. One needed mechanical ventilation. That was in the study."

"You mean an iron lung? An iron lung, sure. Right, right. That don't exist anymore? Caused by a vaccine? Wow. Exactly. Sounds familiar. I think I've heard that before. Journalists, I'm reading this and I look and they had to correct this article, the safety roadblock article. And what did they say? Well, apparently the FDA was really looking out for us because they found this."

"Well, the author says, correction, December 11th, this story has been updated to make it clear that Moderna informed the FDA of the safety findings that triggered the study pause, not the other way around, Biospace regressed the error. So yet another journalist is finding out the FDA is not monitoring these things. They're relying on the company to go."

"Oops, our problem. And sometimes the company doesn't say oops, our problem. But let's look at the study, the actual study trial, because this is interesting. They had two interventions. They had two different types of RSV vaccine. They're both mRNA. This is where these vaccine industries are going, this new technology. But you see against a placebo."

"So this is a very big story that they use the placebo, an inert placebo. Amazing. So just to be clear here for everyone watching, guess again. All of you reporters, one of the things that you've said is misinformation is that we say no placebo-based trials were used in the pre-licensure phase of the 16 vaccines on the childhood, CDC childhood schedule."

"And here we're being proven wrong by a brand new trial. But I mean, what's interesting, Jeffrey, is this proves our point, right? They've never done, and we put out a, we have a document that you can look up and. You know, you can see, you know, whether or not, there it is, it's on our website. You can click right there to see it. It shows all of the safety trials right there on the right, how long they looked at it."

"Did they have a placebo? None of them. There was one tiny placebo group in an HPV vaccine trial, but they hid the data on that. That's a long story. But essentially they've never done it. When they finally do it, when they finally do it on an RSV vaccine program, suddenly they go, whoa, stop. Kids are getting sick."

"People are being injured. Now, normally, if you don't have a placebo group, right? Because they did show that they had one severe illness in that placebo group. So what they would all obviously say without placebo group is kids get sick, RSV, you know, it happens."

"Like, you know, that would be the natural, that, you know, severe illness, needing a respirator, needing an iron lung, that would happen whether they got the vaccine or not. That's what they argue when there's no comparator. But when you actually can compare that group and say, nope, sorry. clearly a different result of the vaccinated compared to the placebo group."

"Now you know why it's so important, New York Times. This is why it's important. By the way, was that trial three days long, Jeffrey? Was it three days? Four days? Five days? They found the problems from what I could see around day 85 to 141 in the trial. So, you know, several months into it that they find these problems. So, so look what happens when you go beyond three days, New York Times. Four days, five..."